Fosamax / Bisphosphonates / Osteoporosis Drugs

Modified on 2011/10/06 02:17 by wschlaht

FDA Fosamax Femur Fractures

The femur is one of the largest and strongest bones in the body. The femur or thigh bone extends from the hip joint down to the knee joint. Because the femur is such a strong bone, it takes tremendous force to cause a femur fracture.

Femur Fracture Causes

A femur fracture might be caused by playing high impact competitive sports, perhaps from a motor vehicle accident, or falling from great heights. Nobody expects a femur fracture after taking bone-building osteoporosis drugs like Fosamax.

Fosamax femur fractures happened to women who were doing what they usually do – rising from a chair or couch or walking across the room. Their behavior was neither risky nor unusual. In patients who suffered femur fractures, their x-rays looked more like a car accident injury than a token fall.

FDA Safety Concerns

On September 9, 2011, two FDA Advisory Committees met to discuss the benefits and risks of long-term bisphosphonates usage for the treatment of osteoporosis. Safety concerns for atypical femur fractures had emerged. These bisphosphonate drugs include Fosamax, Fosamax Plus D, Actonel, Atelvia, Actonel with Calcium, Boniva, and Reclast.

Femur Fracture Exposure

The consumer group, U.S. Drug Watchdog is expanding its national exposure to amplify the risks of femur fractures when taking Fosamax for five years or more and to also identify every woman who has suffered an unexplained broken femur. Their worry is that the average woman taking the drug is not informed by her doctor as to Fosamax femur risks and there is little to no media coverage about Fosamax risks unless a drug is recalled.

Fosamax Revisions

As of this date, Fosamax has not been recalled. Also, none of the FDA panel members recommended firm restrictions on long-term usage nor suggested a black box warning. However, they did recommend increasing the admonitory language on Fosamax, Boniva, and Actonel but didn’t specify what the labels should say. A revised label is expected November 2011.
  Name Size